Histone deacetylase inhibitors for leukemia treatment: current status and future directions.
Antineoplastic agents
Apoptosis
Epigenetics
HDAC inhibitor
Hematological malignancy
Histone deacetylases antagonist
Treatment resistance
Tumor microenvironment
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
09
08
2024
accepted:
13
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Leukemia remains a major therapeutic challenge in clinical oncology. Despite significant advancements in treatment modalities, leukemia remains a significant cause of morbidity and mortality worldwide, as the current conventional therapies are accompanied by life-limiting adverse effects and a high risk of disease relapse. Histone deacetylase inhibitors have emerged as a promising group of antineoplastic agents due to their ability to modulate gene expression epigenetically. In this review, we explore these agents, their mechanisms of action, pharmacokinetics, safety and clinical efficacy, monotherapy and combination therapy strategies, and clinical challenges associated with histone deacetylase inhibitors in leukemia treatment, along with the latest evidence and ongoing studies in the field. In addition, we discuss future directions to optimize the therapeutic potential of these agents.
Identifiants
pubmed: 39456044
doi: 10.1186/s40001-024-02108-8
pii: 10.1186/s40001-024-02108-8
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
514Informations de copyright
© 2024. The Author(s).
Références
Tebbi CK. Etiology of acute leukemia: a review. Cancers. 2021. https://doi.org/10.3390/cancers13092256 .
doi: 10.3390/cancers13092256
pubmed: 34066700
pmcid: 8125807
Schmidt JA, Hornhardt S, Erdmann F, Sánchez-García I, Fischer U, Schüz J, et al. Risk factors for childhood leukemia: radiation and beyond. Front Public Health. 2021;9: 805757.
doi: 10.3389/fpubh.2021.805757
pubmed: 35004601
pmcid: 8739478
Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918–32.
doi: 10.1001/jama.2023.1946
pubmed: 36943212
Clarke Rachel T, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ. Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. Arch Dis Childhood. 2016;101(10):894–901.
doi: 10.1136/archdischild-2016-311251
Inaba H, Pui CH. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J Clin Med. 2021;10(9):1926.
doi: 10.3390/jcm10091926
pubmed: 33946897
pmcid: 8124693
Du M, Chen W, Liu K, Wang L, Hu Y, Mao Y, et al. The global burden of leukemia and its attributable factors in 204 countries and territories: findings from the global burden of disease 2019 study and projections to 2030. J Oncol. 2022;2022:1612702. https://doi.org/10.1155/2022/1612702 .
doi: 10.1155/2022/1612702
pubmed: 35509847
pmcid: 9061017
Zhao C, Dong H, Xu Q, Zhang Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opin Ther Patents. 2020;30(4):263–74.
doi: 10.1080/13543776.2020.1725470
Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8: 576946.
doi: 10.3389/fcell.2020.576946
pubmed: 33117804
pmcid: 7552186
Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372–80.
doi: 10.1002/cncr.34974
pubmed: 37560925
Verza FA, Das U, Fachin AL, Dimmock JR, Marins M. Roles of histone deacetylases and inhibitors in anticancer therapy. Cancers. 2020;12(6):1664.
doi: 10.3390/cancers12061664
pubmed: 32585896
pmcid: 7352721
Lee HT, Oh S, Yoo H, Kwon YW. The key role of DNA methylation and histone acetylation in epigenetics of atherosclerosis. J Lipid Atheroscl. 2020;9(3):419.
doi: 10.12997/jla.2020.9.3.419
Ruzic D, Djoković N, Srdić-Rajić T, Echeverria C, Nikolic K, Santibanez JF. Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14010209 .
doi: 10.3390/pharmaceutics14010209
pubmed: 36559094
pmcid: 9785542
Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016. https://doi.org/10.1101/cshperspect.a026831 .
doi: 10.1101/cshperspect.a026831
pubmed: 27599530
pmcid: 5046688
Ocker M. Deacetylase inhibitors—focus on non-histone targets and effects. World J Biol Chem. 2010;1(5):55–61. https://doi.org/10.4331/wjbc.v1.i5.55 .
doi: 10.4331/wjbc.v1.i5.55
pubmed: 21540990
pmcid: 3083950
San José-Enériz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019. https://doi.org/10.3390/cancers11111794 .
doi: 10.3390/cancers11111794
pubmed: 31739588
pmcid: 6896008
Alseksek RK, Ramadan WS, Saleh E, El-Awady R. The role of HDACs in the response of cancer cells to cellular stress and the potential for therapeutic intervention. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23158141 .
doi: 10.3390/ijms23158141
pubmed: 35897717
pmcid: 9331760
Gong P, Wang Y, Jing Y. Apoptosis induction by histone deacetylase inhibitors in cancer cells: role of Ku70. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20071601 .
doi: 10.3390/ijms20071601
pubmed: 31881689
pmcid: 6981527
Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci CMLS. 2014;71(20):3885–901. https://doi.org/10.1007/s00018-014-1656-6 .
doi: 10.1007/s00018-014-1656-6
pubmed: 24898083
Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci USA. 2012;109(17):6561–5. https://doi.org/10.1073/pnas.1204429109 .
doi: 10.1073/pnas.1204429109
pubmed: 22493260
pmcid: 3340088
Ghelli Luserna di Rora A, Iacobucci I, Martinelli G. The cell cycle checkpoint inhibitors in the treatment of leukemias. J Hematol Oncol. 2017;10(1):77. https://doi.org/10.1186/s13045-017-0443-x .
doi: 10.1186/s13045-017-0443-x
pubmed: 28356161
pmcid: 5371185
Stephen NM, Deepika UR, Maradagi T, Sugawara T, Hirata T, Ganesan P. Insight on the cellular and molecular basis of blood vessel formation: a specific focus on tumor targets and therapy. MedComm Oncol. 2023;2(1): e22. https://doi.org/10.1002/mog2.22 .
doi: 10.1002/mog2.22
Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009;280(2):145–53. https://doi.org/10.1016/j.canlet.2008.11.012 .
doi: 10.1016/j.canlet.2008.11.012
pubmed: 19111391
Jin G, Bausch D, Knightly T, Liu Z, Li Y, Liu B, et al. Histone deacetylase inhibitors enhance endothelial cell sprouting angiogenesis in vitro. Surgery. 2011;150(3):429–35. https://doi.org/10.1016/j.surg.2011.07.001 .
doi: 10.1016/j.surg.2011.07.001
pubmed: 21878227
Kuljaca S, Liu T, Tee AEL, Haber M, Norris MD, Dwarte T, et al. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer. 2007;6(1):68. https://doi.org/10.1186/1476-4598-6-68 .
doi: 10.1186/1476-4598-6-68
pubmed: 17958916
pmcid: 2173905
Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011;3(2):166–79.
pubmed: 21416059
Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 2023;14(9):587. https://doi.org/10.1038/s41419-023-06110-6 .
doi: 10.1038/s41419-023-06110-6
pubmed: 37666813
pmcid: 10477351
Karagiannis D, Rampias T. HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity. Cancers. 2021. https://doi.org/10.3390/cancers13143575 .
doi: 10.3390/cancers13143575
pubmed: 34830883
pmcid: 8616247
Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014;143(3):323–36. https://doi.org/10.1016/j.pharmthera.2014.04.004 .
doi: 10.1016/j.pharmthera.2014.04.004
pubmed: 24769080
pmcid: 4117710
Zhang B, Lyu J, Yang EJ, Liu Y, Wu C, Pardeshi L, et al. Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells. Acta Pharmaceutica Sinica B. 2020;10(4):615–27. https://doi.org/10.1016/j.apsb.2019.08.008 .
doi: 10.1016/j.apsb.2019.08.008
pubmed: 32322466
Mrakovcic M, Bohner L, Hanisch M, Fröhlich LF. Epigenetic targeting of autophagy via HDAC inhibition in tumor cells: role of p53. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19123952 .
doi: 10.3390/ijms19123952
pubmed: 30544838
pmcid: 6321134
Park SY, Kim JS. A short guide to histone deacetylases including recent progress on class II enzymes. Exp Mol Med. 2020;52(2):204–12. https://doi.org/10.1038/s12276-020-0382-4 .
doi: 10.1038/s12276-020-0382-4
pubmed: 32071378
pmcid: 7062823
Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4): a018713. https://doi.org/10.1101/cshperspect.a018713 .
doi: 10.1101/cshperspect.a018713
pubmed: 24691964
pmcid: 3970420
Porter NJ, Christianson DW. Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases. Curr Opin Struct Biol. 2019;59:9–18. https://doi.org/10.1016/j.sbi.2019.01.004 .
doi: 10.1016/j.sbi.2019.01.004
pubmed: 30743180
pmcid: 6687579
Schemies J, Uciechowska U, Sippl W, Jung M. NAD(+)-dependent histone deacetylases (sirtuins) as novel therapeutic targets. Med Res Rev. 2010;30(6):861–89. https://doi.org/10.1002/med.20178 .
doi: 10.1002/med.20178
pubmed: 19824050
Abdallah DI, de Araujo ED, Patel NH, Hasan LS, Moriggl R, Krämer OH, et al. Medicinal chemistry advances in targeting class I histone deacetylases. Explor Target Anti-Tumor Ther. 2023;4(4):757–79. https://doi.org/10.37349/etat.2023.00166 .
doi: 10.37349/etat.2023.00166
Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5. https://doi.org/10.1186/1756-8722-3-5 .
doi: 10.1186/1756-8722-3-5
pubmed: 20132536
pmcid: 2827364
Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma - novel and emerging therapies. Cancer Manag Res. 2013;5:251–69. https://doi.org/10.2147/cmar.s34273 .
doi: 10.2147/cmar.s34273
pubmed: 24049458
pmcid: 3775637
Moran B, Davern M, Reynolds JV, Donlon NE, Lysaght J. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. Cancer Lett. 2023;559: 216121. https://doi.org/10.1016/j.canlet.2023.216121 .
doi: 10.1016/j.canlet.2023.216121
pubmed: 36893893
Shin HS, Choi J, Lee J, Lee SY. Histone deacetylase as a valuable predictive biomarker and therapeutic target in immunotherapy for non-small cell lung cancer. Cancer Res Treat. 2022;54(2):458–68. https://doi.org/10.4143/crt.2021.425 .
doi: 10.4143/crt.2021.425
pubmed: 34517693
Zhang Q, Wang S, Chen J, Yu Z. Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas. Int J Med Sci. 2019;16(3):424–42. https://doi.org/10.7150/ijms.30154 .
doi: 10.7150/ijms.30154
pubmed: 30911277
pmcid: 6428980
Zhang Y, Zhang G, Wang Y, Ye L, Peng L, Shi R, et al. Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review. Front Oncol. 2024;14:1324859. https://doi.org/10.3389/fonc.2024.1324859 .
doi: 10.3389/fonc.2024.1324859
pubmed: 38450195
pmcid: 10915758
Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W, et al. Targeting histone deacetylases for cancer therapy: trends and challenges. Acta pharmaceutica Sinica B. 2023;13(6):2425–63. https://doi.org/10.1016/j.apsb.2023.02.007 .
doi: 10.1016/j.apsb.2023.02.007
pubmed: 37425042
pmcid: 10326266
Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4(4):505–24. https://doi.org/10.4155/fmc.12.3 .
doi: 10.4155/fmc.12.3
pubmed: 22416777
Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018. https://doi.org/10.3389/fonc.2018.00092 .
doi: 10.3389/fonc.2018.00092
pubmed: 29651407
pmcid: 5884928
Chen J, Ren JJ, Cai J, Wang X. Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: a systematic review and meta-analysis. Medicine. 2021;100(31): e26788. https://doi.org/10.1097/md.0000000000026788 .
doi: 10.1097/md.0000000000026788
pubmed: 34397830
pmcid: 8341361
Gao X, Shen L, Li X, Liu J. Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: systematic review and meta-analysis of clinical trials. Exp Ther Med. 2019;18(2):1057–68. https://doi.org/10.3892/etm.2019.7704 .
doi: 10.3892/etm.2019.7704
pubmed: 31363365
pmcid: 6614737
Sochacka-Ćwikła A, Mączyński M, Regiec A. FDA-approved drugs for hematological malignancies-the last decade review. Cancers. 2021. https://doi.org/10.3390/cancers14010087 .
doi: 10.3390/cancers14010087
pubmed: 35008250
pmcid: 8750348
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542–60. https://doi.org/10.1038/s41375-018-0040-1 .
doi: 10.1038/s41375-018-0040-1
pubmed: 29720735
pmcid: 6035147
Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135–43. https://doi.org/10.1016/j.ctrv.2017.11.009 .
doi: 10.1016/j.ctrv.2017.11.009
pubmed: 29304463
Agarwal MA, Sridharan A, Pimentel RC, Markowitz SM, Rosenfeld LE, Fradley MG, et al. Ventricular arrhythmia in cancer patients: mechanisms, treatment strategies and future avenues. Arrhyth Electrophysiol Rev. 2023;12: e16. https://doi.org/10.15420/aer.2023.04 .
doi: 10.15420/aer.2023.04
Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, Afshan S, Halasa M. Vorinostat (SAHA) and breast cancer: an overview. Cancers. 2021. https://doi.org/10.3390/cancers13184700 .
doi: 10.3390/cancers13184700
pubmed: 34572928
pmcid: 8468501
Mohapatra TK, Nayak RR, Ganeshpurkar A, Tiwari P, Kumar D. Opportunities and difficulties in the repurposing of HDAC inhibitors as antiparasitic agents. Drugs Drug Candidates. 2024;3(1):70–101.
doi: 10.3390/ddc3010006
Bubna AK. Vorinostat-an overview. Indian J Dermatol. 2015;60(4):419. https://doi.org/10.4103/0019-5154.160511 .
doi: 10.4103/0019-5154.160511
pubmed: 26288427
pmcid: 4533557
Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Center. 2022;2(4):277–90. https://doi.org/10.1016/j.jncc.2022.09.002 .
doi: 10.1016/j.jncc.2022.09.002
Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009;2:31. https://doi.org/10.1186/1756-8722-2-31 .
doi: 10.1186/1756-8722-2-31
pubmed: 19635146
pmcid: 2731787
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247–52. https://doi.org/10.1634/theoncologist.12-10-1247 .
doi: 10.1634/theoncologist.12-10-1247
pubmed: 17962618
Lohitesh K, Saini H, Srivastava A, Mukherjee S, Roy A, Chowdhury R. Autophagy inhibition potentiates SAHA-mediated apoptosis in glioblastoma cells by accumulation of damaged mitochondria. Oncol Rep. 2018;39(6):2787–96. https://doi.org/10.3892/or.2018.6373 .
doi: 10.3892/or.2018.6373
pubmed: 29658588
Mayr C, Kiesslich T, Erber S, Bekric D, Dobias H, Beyreis M, et al. HDAC screening identifies the HDAC class I inhibitor romidepsin as a promising epigenetic drug for biliary tract cancer. Cancers. 2021. https://doi.org/10.3390/cancers13153862 .
doi: 10.3390/cancers13153862
pubmed: 34439151
pmcid: 8392278
Petrich A, Nabhan C. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leuk Lymphoma. 2016;57(8):1755–65. https://doi.org/10.3109/10428194.2016.1160082 .
doi: 10.3109/10428194.2016.1160082
pubmed: 27118119
pmcid: 4950458
Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent progress in histone deacetylase inhibitors as anticancer agents. Curr Med Chem. 2020;27(15):2449–93. https://doi.org/10.2174/0929867325666181016163110 .
doi: 10.2174/0929867325666181016163110
pubmed: 30332940
Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5(10): e357. https://doi.org/10.1038/bcj.2015.83 .
doi: 10.1038/bcj.2015.83
pubmed: 26473529
pmcid: 4635192
Barbarotta L, Hurley K. Romidepsin for the treatment of peripheral T-cell lymphoma. J Adv Pract Oncol. 2015;6(1):22–36.
pubmed: 26413372
pmcid: 4577031
Stein RA. Epigenetic therapies—a new direction in clinical medicine. Int J Clin Pract. 2014;68(7):802–11. https://doi.org/10.1111/ijcp.12436 .
doi: 10.1111/ijcp.12436
pubmed: 24845064
Pojani E, Barlocco D. Romidepsin (FK228), a histone deacetylase inhibitor and its analogues in cancer chemotherapy. Curr Med Chem. 2021;28(7):1290–303. https://doi.org/10.2174/0929867327666200203113926 .
doi: 10.2174/0929867327666200203113926
pubmed: 32013816
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Recent developments of HDAC inhibitors: Emerging indications and novel molecules. Br J Clin Pharmacol. 2021;87(12):4577–97. https://doi.org/10.1111/bcp.14889 .
doi: 10.1111/bcp.14889
pubmed: 33971031
Hrgovic I, Doll M, Kleemann J, Wang XF, Zoeller N, Pinter A, et al. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways. BMC Cancer. 2016;16(1):763. https://doi.org/10.1186/s12885-016-2807-y .
doi: 10.1186/s12885-016-2807-y
pubmed: 27716272
pmcid: 5045659
Wang B, Wang XB, Chen LY, Huang L, Dong RZ. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013;437(1):1–6. https://doi.org/10.1016/j.bbrc.2013.05.090 .
doi: 10.1016/j.bbrc.2013.05.090
pubmed: 23743198
El Omari N, Bakrim S, Khalid A, Albratty M, Abdalla AN, Lee LH, et al. Anticancer clinical efficiency and stochastic mechanisms of belinostat. Biomed Pharmacother Biomed Pharmacother. 2023;165: 115212. https://doi.org/10.1016/j.biopha.2023.115212 .
doi: 10.1016/j.biopha.2023.115212
pubmed: 37541175
Kusaczuk M, Krętowski R, Stypułkowska A, Cechowska-Pasko M. Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor—belinostat—in glioblastoma cell lines: a preliminary report. Invest New Drugs. 2016;34(5):552–64. https://doi.org/10.1007/s10637-016-0372-5 .
doi: 10.1007/s10637-016-0372-5
pubmed: 27468826
pmcid: 5007275
Singh A, Patel VK, Jain DK, Patel P, Rajak H. Panobinostat as pan-deacetylase inhibitor for the treatment of pancreatic cancer: recent progress and future prospects. Oncol Ther. 2016;4(1):73–89. https://doi.org/10.1007/s40487-016-0023-1 .
doi: 10.1007/s40487-016-0023-1
pubmed: 28261641
Sivaraj D, Green MM, Gasparetto C. Panobinostat for the management of multiple myeloma. Future Oncol (London, England). 2017;13(6):477–88. https://doi.org/10.2217/fon-2016-0329 .
doi: 10.2217/fon-2016-0329
Pan D, Mouhieddine TH, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, et al. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Semin Oncol. 2023;50(1):40–8. https://doi.org/10.1053/j.seminoncol.2023.03.006 .
doi: 10.1053/j.seminoncol.2023.03.006
pubmed: 37005144
Raedler LA. Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits. 2016;9:84–7.
pubmed: 27668050
pmcid: 5013857
Jiang XJ, Huang KK, Yang M, Qiao L, Wang Q, Ye JY, et al. Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways. Cancer Lett. 2012;326(2):135–42. https://doi.org/10.1016/j.canlet.2012.07.030 .
doi: 10.1016/j.canlet.2012.07.030
pubmed: 22863538
Morabito F, Voso MT, Hohaus S, Gentile M, Vigna E, Recchia AG, et al. Panobinostat for the treatment of acute myelogenous leukemia. Expert Opin Investig Drugs. 2016;25(9):1117–31. https://doi.org/10.1080/13543784.2016.1216971 .
doi: 10.1080/13543784.2016.1216971
pubmed: 27485472
Kobayashi Y, Gélinas C, Dougherty JP. Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells. J Gen Virol. 2017;98(4):799–809. https://doi.org/10.1099/jgv.0.000716 .
doi: 10.1099/jgv.0.000716
pubmed: 28113052
pmcid: 5657027
Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901–9. https://doi.org/10.1007/s00280-011-1766-x .
doi: 10.1007/s00280-011-1766-x
pubmed: 22080169
Yuan XG, Huang YR, Yu T, Jiang HW, Xu Y, Zhao XY. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner. Oncol Lett. 2019;18(1):411–9. https://doi.org/10.3892/ol.2019.10301 .
doi: 10.3892/ol.2019.10301
pubmed: 31289512
pmcid: 6540238
He Y, Jiang D, Zhang K, Zhu Y, Zhang J, Wu X, et al. Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy. J Cancer. 2021;12(20):6198–208. https://doi.org/10.7150/jca.61602 .
doi: 10.7150/jca.61602
pubmed: 34539893
pmcid: 8425211
Jiang X, Jiang L, Cheng J, Chen F, Ni J, Yin C, et al. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. J Transl Med. 2021;19(1):117. https://doi.org/10.1186/s12967-021-02789-3 .
doi: 10.1186/s12967-021-02789-3
pubmed: 33743723
pmcid: 7981995
Liu W, Zhao D, Liu T, Niu T, Song Y, Xu W, et al. A multi-center, real-world study of chidamide for patients with relapsed or refractory peripheral T-cell lymphomas in China. Front Oncol. 2021;11: 750323. https://doi.org/10.3389/fonc.2021.750323 .
doi: 10.3389/fonc.2021.750323
pubmed: 34804937
pmcid: 8602952
Connolly RM, Rudek MA, Piekarz R. Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol (London, England). 2017;13(13):1137–48. https://doi.org/10.2217/fon-2016-0526 .
doi: 10.2217/fon-2016-0526
Zeyn Y, Hausmann K, Halilovic M, Beyer M, Ibrahim HS, Brenner W, et al. Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3. Leukemia. 2023;37(11):2319–23. https://doi.org/10.1038/s41375-023-02036-2 .
doi: 10.1038/s41375-023-02036-2
pubmed: 37735559
pmcid: 10624624
Zhou Z, Fang Q, Li P, Ma D, Zhe N, Ren M, et al. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway. Life Sci. 2019;232: 116583. https://doi.org/10.1016/j.lfs.2019.116583 .
doi: 10.1016/j.lfs.2019.116583
pubmed: 31226417
Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol. 2016;172(3):384–91. https://doi.org/10.1111/bjh.13832 .
doi: 10.1111/bjh.13832
pubmed: 26577691
Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, et al. Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: a phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res. 2017;23(11):2691–701. https://doi.org/10.1158/1078-0432.ccr-16-1729 .
doi: 10.1158/1078-0432.ccr-16-1729
pubmed: 27979916
Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs. 2011;20(6):823–9. https://doi.org/10.1517/13543784.2011.577737 .
doi: 10.1517/13543784.2011.577737
pubmed: 21554162
pmcid: 5206967
Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011;12(13):1222–8. https://doi.org/10.1016/S1470-2045(11)70265-0 .
doi: 10.1016/S1470-2045(11)70265-0
pubmed: 22033282
pmcid: 5042214
Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules (Basel, Switzerland). 2015;20(3):3898–941. https://doi.org/10.3390/molecules20033898 .
doi: 10.3390/molecules20033898
pubmed: 25738536
Pinazza M, Borga C, Agnusdei V, Minuzzo S, Fossati G, Paganin M, et al. An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death Dis. 2016;6(1): e2047. https://doi.org/10.1038/cddis.2015.394 .
doi: 10.1038/cddis.2015.394
pubmed: 26764573
Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs. 2020;29(6):525–36. https://doi.org/10.1080/13543784.2020.1761323 .
doi: 10.1080/13543784.2020.1761323
pubmed: 32693648
pmcid: 7534842
Roy R, Ria T, RoyMahaPatra D, Sk UH. Single inhibitors versus dual inhibitors: role of HDAC in cancer. ACS Omega. 2023;8(19):16532–44. https://doi.org/10.1021/acsomega.3c00222 .
doi: 10.1021/acsomega.3c00222
pubmed: 37214715
pmcid: 10193415
Landsburg DJ, Barta SK, Ramchandren R, Batlevi C, Iyer S, Kelly K, et al. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol. 2021;195(2):201–9. https://doi.org/10.1111/bjh.17730 .
doi: 10.1111/bjh.17730
pubmed: 34341990
Jo JH, Jung DE, Lee HS, Park SB, Chung MJ, Park JY, et al. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Int J Cancer. 2022;151(9):1565–77. https://doi.org/10.1002/ijc.34144 .
doi: 10.1002/ijc.34144
pubmed: 35657348
pmcid: 9545559
Moreira-Silva F, Camilo V, Gaspar V, Mano JF, Henrique R, Jerónimo C. Repurposing old drugs into new epigenetic inhibitors: promising candidates for cancer treatment? Pharmaceutics. 2020. https://doi.org/10.3390/pharmaceutics12050410 .
doi: 10.3390/pharmaceutics12050410
pubmed: 32365701
pmcid: 7284583
Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9(1):92. https://doi.org/10.1038/s41392-024-01808-1 .
doi: 10.1038/s41392-024-01808-1
pubmed: 38637540
pmcid: 11026526
Bouyahya A, El Omari N, Bakha M, Aanniz T, El Menyiy N, El Hachlafi N, et al. Pharmacological properties of trichostatin A, focusing on the anticancer potential: a comprehensive review. Pharmaceuticals. 2022;15(10):1235.
doi: 10.3390/ph15101235
pubmed: 36297347
pmcid: 9612318
Peiffer L, Poll-Wolbeck SJ, Flamme H, Gehrke I, Hallek M, Kreuzer KA. Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation. J Cancer Res Clin Oncol. 2014;140(8):1283–93. https://doi.org/10.1007/s00432-014-1689-0 .
doi: 10.1007/s00432-014-1689-0
pubmed: 24793644
Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP, et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer (Oxford, England: 1990). 2003;39(8):1165–75. https://doi.org/10.1016/s0959-8049(03)00072-8 .
doi: 10.1016/s0959-8049(03)00072-8
Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem. 2002;277(3):2073–80. https://doi.org/10.1074/jbc.M106699200 .
doi: 10.1074/jbc.M106699200
pubmed: 11698395
Liu L, Liu H, Liu L, Huang Q, Yang C, Cheng P, et al. Apicidin confers promising therapeutic effect on acute myeloid leukemia cells via increasing QPCT expression. Cancer Biol Ther. 2023;24(1):2228497. https://doi.org/10.1080/15384047.2023.2228497 .
doi: 10.1080/15384047.2023.2228497
pubmed: 37381175
pmcid: 10312027
Fredly H, Gjertsen BT, Bruserud Ø. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenet. 2013;5(1):12. https://doi.org/10.1186/1868-7083-5-12 .
doi: 10.1186/1868-7083-5-12
Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D, et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica. 2007;92(4):542–5. https://doi.org/10.3324/haematol.10758 .
doi: 10.3324/haematol.10758
pubmed: 17488665
Wen J, Chen Y, Yang J, Dai C, Yu S, Zhong W, et al. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia. J ImmunoTher Cancer. 2023;11(7): e006857. https://doi.org/10.1136/jitc-2023-006857 .
doi: 10.1136/jitc-2023-006857
pubmed: 37524506
pmcid: 10391797
Jenke R, Reßing N, Hansen FK, Aigner A, Büch T. Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. 2021;13(4):634.
doi: 10.3390/cancers13040634
pubmed: 33562653
pmcid: 7915831
Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, Behnam B. Overcoming chemotherapy resistance in metastatic cancer: a comprehensive review. Biomedicines. 2024;12(1):183.
doi: 10.3390/biomedicines12010183
pubmed: 38255288
pmcid: 10812960
Hontecillas-Prieto L, Flores-Campos R, Silver A, de Álava E, Hajji N, García-Domínguez DJ. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet. 2020;11: 578011. https://doi.org/10.3389/fgene.2020.578011 .
doi: 10.3389/fgene.2020.578011
pubmed: 33024443
pmcid: 7516260
McCaw TR, Randall TD, Forero A, Buchsbaum DJ. Modulation of antitumor immunity with histone deacetylase inhibitors. Immunotherapy. 2017;9(16):1359–72. https://doi.org/10.2217/imt-2017-0134 .
doi: 10.2217/imt-2017-0134
pubmed: 29185390
pmcid: 6077764
Shanmugam G, Rakshit S, Sarkar K. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Transl Oncol. 2022;16: 101312. https://doi.org/10.1016/j.tranon.2021.101312 .
doi: 10.1016/j.tranon.2021.101312
pubmed: 34922087
Hasanali ZS, Saroya BS, Stuart A, Shimko S, Evans J, Vinod SM, et al. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Sci Transl Med. 2015;7(293): 293ra102. https://doi.org/10.1126/scitranslmed.aaa5079 .
doi: 10.1126/scitranslmed.aaa5079
pubmed: 26109102
pmcid: 4807901
Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Res. 2022;32(5):324–33. https://doi.org/10.1097/cmr.0000000000000818 .
doi: 10.1097/cmr.0000000000000818
pubmed: 35678233
pmcid: 9444873
Hosseini MS, Akbarzadeh MA, Jadidi-Niaragh F. Myeloid-Derived Suppressor Cells and Macrophage Polarization in Cancer Immunotherapy. Critical Developments in Cancer Immunotherapy. IGI Global. 2024;157–204. https://doi.org/10.4018/979-8-3693-3976-3.ch005 .
Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, et al. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10(5):723–33. https://doi.org/10.1016/j.apsb.2019.09.006 .
doi: 10.1016/j.apsb.2019.09.006
pubmed: 32528824
Wachholz V, Mustafa AM, Zeyn Y, Henninger SJ, Beyer M, Dzulko M, et al. Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022;96(1):177–93. https://doi.org/10.1007/s00204-021-03174-1 .
doi: 10.1007/s00204-021-03174-1
pubmed: 34665271
Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https://doi.org/10.1038/s41392-021-00791-1 .
doi: 10.1038/s41392-021-00791-1
pubmed: 34824210
pmcid: 8617206
Takahashi S. Combination therapies with kinase inhibitors for acute myeloid leukemia treatment. Hematol Rep. 2023;15(2):331–46. https://doi.org/10.3390/hematolrep15020035 .
doi: 10.3390/hematolrep15020035
pubmed: 37367084
pmcid: 10297912
Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52: 100905. https://doi.org/10.1016/j.blre.2021.100905 .
doi: 10.1016/j.blre.2021.100905
pubmed: 34774343
Majothi S, Adams D, Loke J, Stevens SP, Wheatley K, Wilson JS. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis. Syst Rev. 2020;9(1):285. https://doi.org/10.1186/s13643-020-01540-1 .
doi: 10.1186/s13643-020-01540-1
pubmed: 33287892
pmcid: 7722339
Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (London, England). 2011;7(2):263–83. https://doi.org/10.2217/fon.11.2 .
doi: 10.2217/fon.11.2
Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene. 2006;25(28):3885–93. https://doi.org/10.1038/sj.onc.1209417 .
doi: 10.1038/sj.onc.1209417
pubmed: 16462761
Ling R, Wang J, Fang Y, Yu Y, Su Y, Sun W, et al. HDAC-an important target for improving tumor radiotherapy resistance. Front Oncol. 2023;13:1193637. https://doi.org/10.3389/fonc.2023.1193637 .
doi: 10.3389/fonc.2023.1193637
pubmed: 37503317
pmcid: 10368992
Kumar A, Emdad L, Fisher PB, Das SK. Chapter three—targeting epigenetic regulation for cancer therapy using small molecule inhibitors. In: Landry JW, Das SK, Fisher PB, editors. Advances in cancer research, vol. 158. Academic Press; 2023. p. 73–161.
Pathania R, Ramachandran S, Mariappan G, Thakur P, Shi H, Choi JH, et al. Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. Can Res. 2016;76(11):3224–35. https://doi.org/10.1158/0008-5472.can-15-2249 .
doi: 10.1158/0008-5472.can-15-2249
Huang W, Zhu Q, Shi Z, Tu Y, Li Q, Zheng W, et al. Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer. Cell Death Discov. 2024;10(1):143. https://doi.org/10.1038/s41420-024-01895-7 .
doi: 10.1038/s41420-024-01895-7
pubmed: 38490978
pmcid: 10943227
Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019–28. https://doi.org/10.1038/leu.2008.397 .
doi: 10.1038/leu.2008.397
pubmed: 19194470
Blagitko-Dorfs N, Schlosser P, Greve G, Pfeifer D, Meier R, Baude A, et al. Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation. Leukemia. 2019;33(4):945–56. https://doi.org/10.1038/s41375-018-0293-8 .
doi: 10.1038/s41375-018-0293-8
pubmed: 30470836
Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, et al. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem. 2021;226: 113825. https://doi.org/10.1016/j.ejmech.2021.113825 .
doi: 10.1016/j.ejmech.2021.113825
pubmed: 34562854
pmcid: 9363153
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28(8):1776–87. https://doi.org/10.1093/annonc/mdx157 .
doi: 10.1093/annonc/mdx157
pubmed: 28838216
Borcoman E, Kamal M, Marret G, Dupain C, Castel-Ajgal Z, Le Tourneau C. HDAC Inhibition to Prime Immune Checkpoint Inhibitors. Cancers. 2021. https://doi.org/10.3390/cancers14010066 .
doi: 10.3390/cancers14010066
pubmed: 35008230
pmcid: 8750966
Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30(4):1035–43. https://doi.org/10.1038/s41591-024-02813-1 .
doi: 10.1038/s41591-024-02813-1
pubmed: 38438735
Gao M, Chen G, Wang H, Xie B, Hu L, Kong Y, et al. Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma. Oncotarget. 2016;7(20):29102–15. https://doi.org/10.18632/oncotarget.8667 .
doi: 10.18632/oncotarget.8667
pubmed: 27074555
pmcid: 5045381
Chao MW, Lai MJ, Liou JP, Chang YL, Wang JC, Pan SL, et al. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol. 2015;8:82. https://doi.org/10.1186/s13045-015-0176-7 .
doi: 10.1186/s13045-015-0176-7
pubmed: 26156322
pmcid: 4504084
Young CS, Clarke KM, Kettyle LM, Thompson A, Mills KI. Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget. 2017;8(31):51429–46. https://doi.org/10.18632/oncotarget.18009 .
doi: 10.18632/oncotarget.18009
pubmed: 28881658
pmcid: 5584259
Valdez BC, Yuan B, Murray D, Nieto Y, Popat U, Andersson BS. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma. 2022;63(7):1634–44. https://doi.org/10.1080/10428194.2022.2042689 .
doi: 10.1080/10428194.2022.2042689
pubmed: 35188042
Jia X, Zheng Y, Guo Y, Chen K. Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways. Mol Genet Genomic Med. 2019;7(5): e613. https://doi.org/10.1002/mgg3.613 .
doi: 10.1002/mgg3.613
pubmed: 30891950
pmcid: 6503025
Moreno DA, Junior HLR, Laranjeira ABA, Cruzeiro GAV, Borges KS, Salomão KB, et al. Panobinostat (LBH589) increase survival in adult xenografic model of acute lymphoblastic leukemia with t(4;11) but promotes antagonistic effects in combination with MTX and 6MP. Medical Oncol (Northwood, London, England). 2022;39(12):216. https://doi.org/10.1007/s12032-022-01813-w .
doi: 10.1007/s12032-022-01813-w
Vagapova E, Kozlov M, Lebedev T, Ivanenko K, Leonova O, Popenko V, et al. Selective inhibition of HDAC class I sensitizes leukemia and neuroblastoma cells to anticancer drugs. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9121846 .
doi: 10.3390/biomedicines9121846
pubmed: 34944663
pmcid: 8698907
Diamanti P, Cox CV, Blair A, Kearns PR. Investigation of the efficacy of PXD101 (Belinostat) on primary leukaemic cells and cell lines as a novel agent for childhood acute lymphoblastic leukaemia (ALL). Blood. 2007;110(11):2793. https://doi.org/10.1182/blood.V110.11.2793.2793 .
doi: 10.1182/blood.V110.11.2793.2793
Valiuliene G, Stirblyte I, Cicenaite D, Kaupinis A, Valius M, Navakauskiene R. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling. J Cell Mol Med. 2015;19(7):1742–55. https://doi.org/10.1111/jcmm.12550 .
doi: 10.1111/jcmm.12550
pubmed: 25864732
pmcid: 4511371
Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, Spiekermann K, et al. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors. Mol Cancer Ther. 2012;11(11):2373–83. https://doi.org/10.1158/1535-7163.mct-12-0129 .
doi: 10.1158/1535-7163.mct-12-0129
pubmed: 22942377
Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008;14(2):549–58. https://doi.org/10.1158/1078-0432.ccr-07-1934 .
doi: 10.1158/1078-0432.ccr-07-1934
pubmed: 18223231
Alves Silva PH, Xing S, Kotini AG, Papapetrou EP, Song X, Wucherpfennig KW, et al. MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia. Blood. 2022;139(2):205–16. https://doi.org/10.1182/blood.2021011619 .
doi: 10.1182/blood.2021011619
He B, Wang Q, Liu X, Lu Z, Han J, Pan C, et al. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother. 2020;129: 110390. https://doi.org/10.1016/j.biopha.2020.110390 .
doi: 10.1016/j.biopha.2020.110390
pubmed: 32563150
Zhao H, Jiang Y, Lin F, Zhong M, Tan J, Zhou Y, et al. Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells. Exp Hematol Oncol. 2022;11(1):29. https://doi.org/10.1186/s40164-022-00282-1 .
doi: 10.1186/s40164-022-00282-1
pubmed: 35581670
pmcid: 9112613
Hu C, Fu X, Li S, Chen C, Zhao X, Peng J. Chidamide inhibits cell glycolysis in acute myeloid leukemia by decreasing N6-methyladenosine-related GNAS-AS1. Daru J Faculty Pharm Tehran Univ Med Sci. 2024;32(1):11–24. https://doi.org/10.1007/s40199-023-00482-y .
doi: 10.1007/s40199-023-00482-y
Gu S, Hou Y, Dovat K, Dovat S, Song C, Ge Z. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023;12(1):23. https://doi.org/10.1186/s40164-023-00383-5 .
doi: 10.1186/s40164-023-00383-5
pubmed: 36849955
pmcid: 9972767
Yin L, Zhang Q, Xie S, Cheng Z, Li R, Zhu H, et al. HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway. Hum Cell. 2023;36(4):1564–77. https://doi.org/10.1007/s13577-023-00919-1 .
doi: 10.1007/s13577-023-00919-1
pubmed: 37222919
Wang B, Lyu H, Pei S, Song D, Ni J, Liu B. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle (Georgetown, Tex). 2018;17(8):985–96. https://doi.org/10.1080/15384101.2018.1464849 .
doi: 10.1080/15384101.2018.1464849
pubmed: 29969371
Zhou L, Ruvolo VR, McQueen T, Chen W, Samudio IJ, Conneely O, et al. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia. 2013;27(6):1358–68. https://doi.org/10.1038/leu.2012.366 .
doi: 10.1038/leu.2012.366
pubmed: 23247046
Golay J, Cuppini L, Leoni F, Micò C, Barbui V, Domenghini M, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007;21(9):1892–900. https://doi.org/10.1038/sj.leu.2404860 .
doi: 10.1038/sj.leu.2404860
pubmed: 17637810
El-Khoury V, Pierson S, Szwarcbart E, Brons NH, Roland O, Cherrier-De WS, et al. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia. 2014;28(8):1636–46. https://doi.org/10.1038/leu.2014.19 .
doi: 10.1038/leu.2014.19
pubmed: 24418989
pmcid: 4131250
Rücker FG, Lang KM, Fütterer M, Komarica V, Schmid M, Döhner H, et al. Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. Epigenetics. 2016;11(7):517–25. https://doi.org/10.1080/15592294.2016.1187350 .
doi: 10.1080/15592294.2016.1187350
pubmed: 27309669
pmcid: 4939918
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, et al. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022;69(10): e29812. https://doi.org/10.1002/pbc.29812 .
doi: 10.1002/pbc.29812
pubmed: 35726868
Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, et al. Vorinostat combined with busulfan, fludarabine, and clofarabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute leukemia: long-term study outcomes. Transplant Cell Ther. 2022;28(8):501.e1-e7. https://doi.org/10.1016/j.jtct.2022.05.021 .
doi: 10.1016/j.jtct.2022.05.021
pubmed: 35618218
Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, et al. Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study. Clin Cancer Res. 2020;26(10):2297–307. https://doi.org/10.1158/1078-0432.ccr-19-1251 .
doi: 10.1158/1078-0432.ccr-19-1251
pubmed: 31969338
pmcid: 7477726
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, et al. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024;38(1):58–66. https://doi.org/10.1038/s41375-023-02073-x .
doi: 10.1038/s41375-023-02073-x
pubmed: 37935977
DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, et al. Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019;85: 106197. https://doi.org/10.1016/j.leukres.2019.106197 .
doi: 10.1016/j.leukres.2019.106197
pubmed: 31541945
pmcid: 7108400
Goldberg J, Sulis ML, Bender J, Jeha S, Gardner R, Pollard J, et al. A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatr Hematol Oncol. 2020;37(6):465–74. https://doi.org/10.1080/08880018.2020.1752869 .
doi: 10.1080/08880018.2020.1752869
pubmed: 32338562
Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, et al. Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: phase I study results. Clin Cancer Res. 2019;25(16):4917–23. https://doi.org/10.1158/1078-0432.ccr-19-0171 .
doi: 10.1158/1078-0432.ccr-19-0171
pubmed: 31152020
Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, et al. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021;5(13):2740–50. https://doi.org/10.1182/bloodadvances.2021004225 .
doi: 10.1182/bloodadvances.2021004225
pubmed: 34242388
pmcid: 8288668
Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81(3):170–6. https://doi.org/10.1111/j.1600-0609.2008.01102.x .
doi: 10.1111/j.1600-0609.2008.01102.x
pubmed: 18510700
Shafer D, Kagan AB, Rudek MA, Kmieciak M, Tombes MB, Shrader E, et al. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer Chemother Pharmacol. 2023;91(3):281–90. https://doi.org/10.1007/s00280-023-04511-0 .
doi: 10.1007/s00280-023-04511-0
pubmed: 36864346
pmcid: 10807611
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, et al. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2021;62(5):1187–94. https://doi.org/10.1080/10428194.2020.1861270 .
doi: 10.1080/10428194.2020.1861270
pubmed: 33356689
Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014;55(10):2301–4. https://doi.org/10.3109/10428194.2013.877134 .
doi: 10.3109/10428194.2013.877134
pubmed: 24369094
pmcid: 4143479
Garcia-Manero G, Kazmierczak M, Wierzbowska A, Fong CY, Keng MK, Ballinari G, et al. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study. Leuk Res. 2024;140: 107480. https://doi.org/10.1016/j.leukres.2024.107480 .
doi: 10.1016/j.leukres.2024.107480
pubmed: 38499457
Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, et al. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma. 2017;58(6):1349–57. https://doi.org/10.1080/10428194.2016.1276287 .
doi: 10.1080/10428194.2016.1276287
pubmed: 28103725
pmcid: 5817887
Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, et al. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023;37(2):433–40. https://doi.org/10.1038/s41375-022-01780-1 .
doi: 10.1038/s41375-022-01780-1
pubmed: 36653509
pmcid: 9898022
Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood. 2011;118(24):6274–83. https://doi.org/10.1182/blood-2011-03-339879 .
doi: 10.1182/blood-2011-03-339879
pubmed: 21911830
Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117(2):336–42. https://doi.org/10.1002/cncr.25584 .
doi: 10.1002/cncr.25584
pubmed: 20862746
Wang L, Luo J, Chen G, Fang M, Wei X, Li Y, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clin Epigenet. 2020;12(1):132. https://doi.org/10.1186/s13148-020-00923-4 .
doi: 10.1186/s13148-020-00923-4
Wei Y, Wang L, Zhu C, Li H, Bo J, Zhang R, et al. A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Med Oncol (Northwood, London, England). 2023;40(2):77. https://doi.org/10.1007/s12032-022-01911-9 .
doi: 10.1007/s12032-022-01911-9
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. https://doi.org/10.1186/s13045-017-0439-6 .
doi: 10.1186/s13045-017-0439-6
pubmed: 28298231
pmcid: 5351273
Carraway HE, Sawalha Y, Gojo I, Lee MJ, Lee S, Tomita Y, et al. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leuk Res. 2021;110: 106707. https://doi.org/10.1016/j.leukres.2021.106707 .
doi: 10.1016/j.leukres.2021.106707
pubmed: 34563945
pmcid: 8915247
Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, et al. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann Hematol. 2024;103(1):105–16. https://doi.org/10.1007/s00277-023-05552-4 .
doi: 10.1007/s00277-023-05552-4
pubmed: 38036712
Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112(4):981–9. https://doi.org/10.1182/blood-2007-10-115873 .
doi: 10.1182/blood-2007-10-115873
pubmed: 18495956
pmcid: 4081529
Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol. 2009;147(4):507–14. https://doi.org/10.1111/j.1365-2141.2009.07881.x .
doi: 10.1111/j.1365-2141.2009.07881.x
pubmed: 19747365
pmcid: 2779118
Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, et al. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 × 2, phase II trial. J Clin Oncol. 2020;38(3):257–70. https://doi.org/10.1200/jco.19.01053 .
doi: 10.1200/jco.19.01053
pubmed: 31794324
Becker H, Schmoor C, Grishina O, Pfeifer D, Zimmer D, Crysandt M, et al. Randomized phase II study of all-trans retinoic acid and valproic acid added to decitabine in newly diagnosed elderly AML patients (DECIDER trial): predictive impact of TP53 status. Blood. 2021;138:2380. https://doi.org/10.1182/blood-2021-146468 .
doi: 10.1182/blood-2021-146468
Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood. 2014;123(26):4027–36. https://doi.org/10.1182/blood-2013-12-546283 .
doi: 10.1182/blood-2013-12-546283
pubmed: 24797300